Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's drug trial halted: what we learned from UCB0599

NCT ID NCT05543252

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether taking UCB0599 early or later could slow brain changes in people with Parkinson's disease. It involved 428 adults who had already completed an earlier study. The trial was stopped early, but researchers measured brain scans and medication use over 18 months to see if the drug had any effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

428 people

The number who actually took part.

Started

Aug 2022

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 78 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Participant completed the Treatment Period of PD0053 (NCT04658186). The Baseline Visit for PD0055 (Visit 2) should be no later than 4 weeks following the end of treatment (EOT) Visit in PD0053 (NCT04658186). Any delay needs to be justified by the Investigator and approved by the Sponsor * A male study participant must agree to use contraception during the Treatment Period and for at least 90 days after the last dose of the IMP and refrain from donating sperm during this period. * A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: ◦ Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 1 month after the last dose of investigational medicinal product (IMP). The study participant must have a negative urine pregnancy test at Screening (Visit 1), which is to be confirmed negative by urine testing prior to the first dose of IMP at PD0055 Baseline Visit. If oral contraception is used, an additional barrier method will be required during the study as an IMP-related gastrointestinal upset or a drug interaction by cytochrome P450 3A4 (CYP3A4) induction could interfere with efficacy * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent form (ICF) and in this protocol. Exclusion Criteria: * Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study * A female study participant who tests positive for pregnancy, plans to get pregnant during the participation in the study, or who is breastfeeding * Study participant had previously participated in PD0055 * Study participant meets any withdrawal criteria in PD0053 (NCT04658186) * Study participants wearing any kind of implantable active device, including cardiac pacemakers, pumps, and implantable cardioverters, will be excluded from using Digital Health Technology, but may participate in the main study * Study participant does not agree to refrain from donating blood or blood products or other body fluids

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease

Contacts and locations

Locations

  • Pd0055 40023

    Erlangen, Germany

  • Pd0055 40045

    A Coruña, Spain

  • Pd0055 40046

    Córdoba, Spain

  • Pd0055 40049

    Seville, Spain

  • Pd0055 40130

    Marseille, France

  • Pd0055 40131

    Strasbourg, France

  • Pd0055 40138

    Bonn, Germany

  • Pd0055 40159

    Barcelona, Spain

  • Pd0055 40174

    Mainz, Germany

  • Pd0055 40175

    London, United Kingdom

  • Pd0055 40249

    Kiel, Germany

  • Pd0055 40257

    Roma, Italy

  • Pd0055 40267

    Barcelona, Spain

  • Pd0055 40306

    Newcastle upon Tyne, United Kingdom

  • Pd0055 40352

    Pamplona, Spain

  • Pd0055 40359

    Nijmegen, Netherlands

  • Pd0055 40424

    Créteil, France

  • Pd0055 40457

    Plymouth, United Kingdom

  • Pd0055 40515

    Berlin, Germany

  • Pd0055 40524

    Nîmes, France

  • Pd0055 40525

    Paris, France

  • Pd0055 40526

    Lille, France

  • Pd0055 40527

    Bordeaux, France

  • Pd0055 40528

    Toulouse, France

  • Pd0055 40529

    Marburg, Germany

  • Pd0055 40530

    Dresden, Germany

  • Pd0055 40531

    Regensburg, Germany

  • Pd0055 40532

    Haag in Oberbayern, Germany

  • Pd0055 40533

    Padova, Italy

  • Pd0055 40534

    Roma, Italy

  • Pd0055 40535

    Oświęcim, Poland

  • Pd0055 40536

    Warsaw, Poland

  • Pd0055 40538

    Krakow, Poland

  • Pd0055 40539

    Katowice, Poland

  • Pd0055 40540

    Madrid, Spain

  • Pd0055 40541

    San Sebastián, Spain

  • Pd0055 40542

    Móstoles, Spain

  • Pd0055 40543

    London, United Kingdom

  • Pd0055 40544

    Motherwell, United Kingdom

  • Pd0055 40555

    Brescia, Italy

  • Pd0055 40635

    Nantes, France

  • Pd0055 40694

    Bydgoszcz, Poland

  • Pd0055 40696

    Krakow, Poland

  • Pd0055 40697

    Terni, Italy

  • Pd0055 40698

    London, United Kingdom

  • Pd0055 40699

    Warsaw, Poland

  • Pd0055 40700

    Lodz, Poland

  • Pd0055 40702

    Lublin, Poland

  • Pd0055 40705

    Warsaw, Poland

  • Pd0055 40710

    Essen, Germany

  • Pd0055 40711

    Erbach im Odenwald, Germany

  • Pd0055 40719

    Jelenia Góra, Poland

  • Pd0055 50074

    Kansas City, Kansas, 66160-8500, United States

  • Pd0055 50084

    Charleston, Oregon, 29425, United States

  • Pd0055 50107

    Burlington, Vermont, 05401, United States

  • Pd0055 50113

    Houston, Texas, 77030, United States

  • Pd0055 50118

    Los Angeles, California, 90033, United States

  • Pd0055 50121

    Lexington, Kentucky, 40536-0284, United States

  • Pd0055 50243

    Boston, Massachusetts, 02114, United States

  • Pd0055 50255

    Columbus, Ohio, 43210-1240, United States

  • Pd0055 50292

    Kirkland, Washington, 98034, United States

  • Pd0055 50310

    Chicago, Illinois, 60612-3863, United States

  • Pd0055 50311

    Cleveland, Ohio, 44195, United States

  • Pd0055 50372

    Cleveland, Ohio, 44121, United States

  • Pd0055 50374

    Calgary, Canada

  • Pd0055 50385

    Fresno, California, 93710, United States

  • Pd0055 50386

    Farmington Hills, Michigan, 48334, United States

  • Pd0055 50387

    Ottawa, Canada

  • Pd0055 50389

    Toronto, Canada

  • Pd0055 50392

    Danbury, Connecticut, 06810, United States

  • Pd0055 50394

    Tampa, Florida, 33613, United States

  • Pd0055 50395

    New Orleans, Louisiana, 70121, United States

  • Pd0055 50396

    Boca Raton, Florida, 33486, United States

  • Pd0055 50397

    Las Vegas, Nevada, 89123, United States

  • Pd0055 50398

    Tulsa, Oklahoma, 74136, United States

  • Pd0055 50399

    Winfield, Illinois, 60190, United States

  • Pd0055 50400

    San Antonio, Texas, 78229-3900, United States

  • Pd0055 50401

    Chicago, Illinois, 60611, United States

  • Pd0055 50402

    Crab Orchard, West Virginia, 25827, United States

  • Pd0055 50410

    Fairfax, Virginia, 22031, United States

  • Pd0055 50506

    Phoenix, Arizona, 85004-1150, United States

  • Pd0055 50519

    Fountain Valley, California, 92708, United States

  • Pd0055 50524

    Bradenton, Florida, 34205, United States

  • Pd0055 50525

    Houston, Texas, 77030, United States

  • Pd0055 50526

    Philadelphia, Pennsylvania, 19107, United States

  • Pd0055 50530

    Stony Brook, New York, 11794, United States

  • Pd0055 50531

    Englewood, Colorado, 80113, United States

  • Pd0055 50534

    Virginia Beach, Virginia, 23456, United States

  • Pd0055 50535

    Williamsville, New York, 14221, United States

  • Pd0055 50536

    Saint Paul, Minnesota, 55130, United States

  • Pd0055 50538

    Farmington, Connecticut, 06030-3805, United States

  • Pd0055 50543

    Memphis, Tennessee, 38157, United States

  • Pd0055 50544

    Augusta, Georgia, 30912-0004, United States

  • Pd0055 50546

    Worcester, Massachusetts, 01655, United States

  • Pd0055 50547

    Baltimore, Maryland, 21287, United States

  • Pd0055 50549

    Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.